West Pharmaceutical Services (NYSE:WST) Updates Q3 2026 Earnings Guidance

West Pharmaceutical Services (NYSE:WST) issued an update on its third quarter 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 2.140-2.240 for the period, compared to the consensus estimate of 2.130. The company issued revenue guidance of $820.0 million-$835.0 million, compared to the consensus revenue estimate of $815.1 million. West Pharmaceutical Services also updated its FY 2026 guidance to 8.850-9.050 EPS.

West Pharmaceutical Services Trading Down 0.1%

NYSE WST opened at $358.87 on Thursday. The business’s 50-day moving average price is $335.41 and its two-hundred day moving average price is $286.58. West Pharmaceutical Services has a 12 month low of $221.50 and a 12 month high of $367.66. The firm has a market capitalization of $25.35 billion, a PE ratio of 47.98, a price-to-earnings-growth ratio of 2.91 and a beta of 1.16. The company has a current ratio of 2.71, a quick ratio of 2.04 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, beating the consensus estimate of $1.68 by $0.45. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The company had revenue of $844.90 million during the quarter, compared to analysts’ expectations of $779.67 million. During the same quarter in the prior year, the firm posted $1.45 earnings per share. The business’s quarterly revenue was up 21.0% on a year-over-year basis. On average, analysts expect that West Pharmaceutical Services will post 8.6 EPS for the current year.

West Pharmaceutical Services Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th will be issued a $0.22 dividend. The ex-dividend date is Wednesday, July 29th. This represents a $0.88 annualized dividend and a yield of 0.2%. West Pharmaceutical Services’s dividend payout ratio is presently 11.76%.

Analysts Set New Price Targets

A number of research firms have weighed in on WST. BNP Paribas Exane began coverage on shares of West Pharmaceutical Services in a research report on Monday, July 13th. They set an “outperform” rating and a $447.00 target price for the company. Morgan Stanley boosted their price target on shares of West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 9th. TD Cowen reaffirmed a “buy” rating on shares of West Pharmaceutical Services in a research note on Wednesday, July 15th. Stephens reiterated an “overweight” rating and set a $360.00 price objective on shares of West Pharmaceutical Services in a research report on Tuesday, June 2nd. Finally, Weiss Ratings raised shares of West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, April 27th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, West Pharmaceutical Services presently has a consensus rating of “Buy” and a consensus price target of $363.17.

Insider Buying and Selling

In related news, CAO Chad Winters sold 896 shares of the business’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $300.67, for a total transaction of $269,400.32. Following the transaction, the chief accounting officer owned 1,523 shares in the company, valued at $457,920.41. The trade was a 37.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Annette F. Favorite sold 2,817 shares of the stock in a transaction on Monday, April 27th. The stock was sold at an average price of $305.20, for a total transaction of $859,748.40. Following the transaction, the vice president directly owned 16,828 shares in the company, valued at approximately $5,135,905.60. This represents a 14.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 0.60% of the company’s stock.

Institutional Trading of West Pharmaceutical Services

Large investors have recently made changes to their positions in the company. CYBER HORNET ETFs LLC bought a new stake in West Pharmaceutical Services in the 2nd quarter valued at about $25,000. DV Equities LLC acquired a new position in West Pharmaceutical Services during the 4th quarter worth approximately $28,000. MUFG Securities EMEA plc bought a new position in West Pharmaceutical Services in the second quarter worth approximately $47,000. State of Wyoming bought a new position in West Pharmaceutical Services in the second quarter worth approximately $49,000. Finally, Meeder Asset Management Inc. grew its stake in West Pharmaceutical Services by 1,023.5% in the fourth quarter. Meeder Asset Management Inc. now owns 191 shares of the medical instruments supplier’s stock valued at $53,000 after acquiring an additional 174 shares during the period. 93.90% of the stock is currently owned by institutional investors and hedge funds.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.